Tasimelteon inhibits glioma proliferation by inducing ferroptosis via the SP1/ACSL4 pathway
Yi Chen, Jicheng Li, Huilan Yang, Haiyang Liang, Ji Shi, Quan Li, Qiang Liu, Jia Liu, Xuanming Zhang, Huizhe Xu, Haozhe Piao · 2026
Read Tasimelteon inhibits glioma proliferation by inducing ferroptosis via the SP1/ACSL4 pathway by Yi Chen, Jicheng Li, Huilan Yang, Haiyang Liang, Ji Shi, Quan Li, Qiang Liu, Jia Liu, Xuanming Zhang, Huizhe Xu, Haozhe Piao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13590473.txt.
Description
Yi Chen and ten colleagues report, in 2026, that a sleep drug may fight glioma, a harsh brain tumor with few good treatments. The drug, tasimelteon, is approved for sleep rhythm disorders and reaches the brain well. In lab tests it slowed glioma cell growth in step with dose and time. The team traced the effect to ferroptosis, a form of cell death driven by iron and fat damage.
Tasimelteon raised a gene called ACSL4 by steadying its switch, a protein named SP1, the team found. In mice with glioma grafted into the brain, the drug curbed tumor growth and lengthened life. No clear harm to major organs showed up. Chen and colleagues offer the drug as a candidate worth testing in patients.
Catalog record
| CREATOR | Yi Chen, Jicheng Li, Huilan Yang, Haiyang Liang, Ji Shi, Quan Li, Qiang Liu, Jia Liu, Xuanming Zhang, Huizhe Xu, Haozhe Piao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45758 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |